Telo Genomics Corp (TSE:TELO) has released an update.
Telo Genomics Corp has expanded its collaboration with Mayo Clinic to enhance the development of its TeloView diagnostic tests for multiple myeloma, aiming to improve patient outcomes and commercialize its innovative technologies. The partnership includes the validation of TeloViewNDMM, a test for predicting the relapse of newly diagnosed multiple myeloma patients, as a Laboratory Developed Test (LDT).
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.
